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For many years, research into human cancer has concentrated on human patients and on artificially
induced neoplasms in inbred murine hosts. Cancer, however, affects a great variety ofmammals, particularly
those that have been domesticated. Such naturally occurring neoplasms are common in dogs, cats, cattle,
horses, etc., and offer fertile ground for studies relating to epidemiology, etiology, immunobiology, and
therapy. Canine osteosarcoma is described in detail. The clinicopathologic features of this canine tumor
closely approximate that of human osteosarcoma and thus make canine osteosarcoma an invaluable
comparative model. Canine osteosarcoma and other naturally occurring tumors lie intermediate between the
mouse models and human cancer. The use ofthese veterinary models in the future fabric of cancer research
will broaden its base and will influence our conceptual approach to research and clinical options.
Neoplasia affects a broad spectrum of vertebrates from fish through amphibia,
reptiles, birds, and mammals. It is not confined to only mouse and man. Each one of
these naturally occurring neoplasms offers yet another clue or clues in the complex
biology of neoplasia-a group of diseases that for the most part still remain poorly
understood, despite the massive application of money and technology. The occur-
rence, therefore, of these neoplasms in a wide range ofvertebrate hosts is offar more
than passing interest. Cancer needs to be studied as a comparative biological problem
and not as a disease restricted to only a few species.
The thrust of this paper will be twofold: (1) to emphasize the great values inherent
in using naturally occurring neoplasms in domestic mammals and (2) to illustrate
these values by reviewing canine osteosarcoma (OS) and comparing it to other
experimental models and to its human counterpart.
Veterinarians have treated cancer in their animal patients for many decades. Only
recently, however, has the great value of these animals been realized. These neo-
plasms occur naturally in largely outbred populations, a condition closely analogous
to that in man. Such tumors have been most closely studied in dogs, cats, and cattle
but much is also known about neoplastic diseases in horses, sheep, goats, and swine
[1]. For the purposes ofthis paper, however, I will concentrate on naturally occurring
solid tumors in dogs.
Do these canine tumors have any value in helping to unravel the mysteries of
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cancer? The answer is a resounding yes. Asidefrom assisting in the treatment ofa sick
animal and helping a distressed owner, the veterinarian may resolve specific ques-
tions relevant to human neoplasia.
Let us first examine some experimentally induced OS in laboratory animals.
LABORATORY MODELS OF OS
This brief review does not attempt to include every experimental production ofOS
ever performed, but rather to familiarize the reader with some ofthe more important
laboratory models.
1. Ridgway OS (ROS): Originally described in 1948 from a spontaneous inguinal
mass in a male AK mouse, it has been established as a transplantable tumor and
maintained in serial passage in AKR mice. Therapeutic trials using ROS employ
AKD2F hybrids as they withstand chemotherapy better than the inbred lines.
Median lifespan of affected mice is 25-35 days. Up to 11 single drugs are known that
will cure mice of this neoplasm. ROS is a highly reproducible model to study drug
interactions and tumor cell kinetics. Clinical staging of affected mice can simulate
different stages of human OS [2].
2. Moloney sarcoma virus inoculated into the tibial medulla of newborn Wistar
Lewis rats results in OS in 97.7 percent of all animals. Lung metastasis develops in
77.9 percent after six weeks. whereas after initial growth of the primary OS, the
remaining 22.1 percent of the tumors regress. Cell-mediated immune response and
serum blocking activity can be demonstrated in vitro, and these results can be
correlated with the clinical stage of the disease [3,4].
3. The implantation of methylcholanthrene into the embryonic odontogenic
tissues of 30 Swiss mice, five months of age, produced a few OS although epithelial
tumors were more common [5].
4. Cupric chelated N-hydroxy-2-acetylaminofluorene injected into the femoral
medulla of 10-16 week old female Osborn-Mendel rats produced various types of
sarcoma including OS in 21 of the 29 animals. Most neoplasms developed from the
soft tissue adjacent to the bones where the carcinogen had leaked out from the
trephine holes. Newer experiments are underway in which the trephine sites are
plugged immediately after injection of the carcinogen. A variety of othercompounds
of nickel, chromium, cobalt, and other standard carcinogens such as benzpyrene and
methylcholanthrene have also induced OS in mice [6].
5. X-irradiation, or the injection of various radionuclides have produced OS in
rabbits, mice, dogs (Beagles), miniature swine, and macaques [7-11]. Young rabbits
given Sr90 I.V. develop OS of the external auditory meatus, a site where these bone-
seeking isotopes tend to accumulate because there is little bone turnover [8]. In
miniature swine the daily feeding of mCi + Sr90 caused OS to develop in the bones of
the skull. OS formation usually coincides with maximal irradiation necrosis of bone
followed by perversion of the repair process [9].
In Beagles given Sr90, OS occurred at the three highest dose levels tested. The
mean induction time was 266 days but the first histologic detection of OS may occur
within 90 days. Only 4 percent of these tumors metastasized and the liver was the
most common organ affected. Most OS arose from the endosteum with only a few
being of metaphyseal origin. The major site of OS in order offrequency was femur,
lumbar spine, tibia, pelvis, sacrum, and thoracic spine. Whether or not irradiation
activates a latent tumor virus is unknown [11].
6. FBJ-Moloney sarcoma virus is the only naturally occurring murine sarcoma
virus. It is unique as it produces mostly OS. In 1966 FBJ virus was isolated from a
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spontaneous OS of the thoracic vertebra in a male CFI/Anl mouse. C-type viral
particles similar to the murine oncorna viruses were detected electronmicroscopi-
cally. Serial passage through newborn CF-l mice can shorten the latency period to 21
days after injection even though the average latent period is 40-60 days. In tissue
cultures both focus-forming sarcoma virus (FBJ-MSV) and associated non-focus
forming leukemia virus(FBJ-MLV) are present. A delicate balance ofFBJ-MSV and
FBJ-MLV is needed for focus induction [12].
There is no question that such simplified laboratory systems have yielded awealth
of information to the cancer biologist. It is not the purpose of this paper to deny the
great worth of such experimental models. Rather, my purpose is to point out that
there is a wide gap between these highly artificialized models and clinical human
cancer. While further simplification of these model systems allows for the construc-
tion of clear conclusions in a particular experiment, one must wonder whether some
of these conclusions are applicable to the natural human disease, the ultimate goal of
such research. Indeed, such highly artificialized systems may at times be muddles
rather than models. Thus while these mouse systems have a great deal to offer in
cancer research, they possess some serious limitations. Until very recently, research in
OS, has been confined almost completely to the development of artificial models of
OS in mice, rats, rabbits, etc., whereas naturally occurring OS in dogs, cats, and
other domestic species has been ignored. We must therefore, in addition, also seek
other models that more closely approximate the disease in man. Such animal models
are commonplace and are seen almost daily bythe average veterinary practitioner. By
broadening the scope ofcancer research into these available domestic animal tumors,
we can learn much more about etiology, epidemiology, immunology, metastasis, and
therapy.
The advantages of these models can be outlined as follows: Neoplasia occurs
naturally in these animals, most of which are outbred-thus closely simulating the
human disease.
Many of these animals (dogs and cats) closely share the human environment.
Because they live far shorter lives than man and tend to be restricted to their
domiciles far more closely than their owners, they offer excellent subjects for research
into environmental causes of cancer. Indeed, a study in the Philadelphia area
indicated that dogs with squamous cell carcinoma of the tonsil were more closely
associated with areas of air pollution than were dogs with primary lung and nasal
carcinomas [13]. Furthermore, there is always the distinct possibility that neoplasia
in these animals may serve as an early warning system for a similar neoplasm in man.
It is now very well known that the reproductive failures in many birds of prey was a
clear signal that the biosphere was heavily contaminated with DDT (dichloro-
diphenyl trichloroethane) [14].
The biological behavior of many canine tumors very closely approximates that of
their human counterparts. In the past decade there has been a great upsurge of
interest in veterinary oncology. Many veterinary schools have oncology units and
good data retrieval systems. A national group, the Veterinary Cancer Society, was
formed in 1973 to unite all those with an interest in these diseases. The present-day
therapy of many canine and feline neoplasms is multidisciplinary and involves all of
the modalities used in the treatment ofsimilardiseases in man. The literature on these
animal neoplasms has shown a tremendous increase and several texts on veterinary
oncology are now in preparation. All of this means that the veterinary profession is
now in an excellent position to play an important role in many facets of cancer
biology.
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Furthermore, the World Health Organization has published a standardized system
of histological diagnosis for canine neoplasms [15] and recently has completed work
on TNM (primary tumor, regional lymph node, distant metastases) clinical staging
systems which are very similar to those being used in humans. There is increasing
cooperation between members of the veterinary profession both nationally and to
some extent internationally.
Because of the much shorter life span of the dog, the manifestations of the
neoplasm are compressed into a much shorter period. Likewise, evaluation of
therapeutic results can be made in a far shorter time period than in man. In general a
one-year survival in the dog or cat is roughly equivalent to a 4-5 year survival in man.
Considerable epidemiological information on canine and feline neoplasms is
already available, particularly that emanating from an extensive study in several
California counties [16-18] as well as from various universityteaching hospitals [19].
It is well known that different breeds ofdogs have different susceptibilities to various
histologic types of tumors in a variety of anatomic sites. For example, Boxer dogs
have a broad range of susceptibility to a host of neoplasms (gastro-intestinal, lung,
lymphoid, testicular, aortic body, thyroid, brain, cutaneous mast cell tumors,
osteosarcoma, etc.) [19,20]. Because of these observations and their apparently
increased susceptibility to systemic mycoses [21-23], great interest has focused on
possible defects in cell-mediated immunity in this breed. Malignant melanoma ofthe
oral cavity, a common canine tumor, has a predilection for heavily pigmented breeds,
particularly the Cocker Spaniel [19]. Suffice it to say that we have a wide range of
naturally occurring tumors in our domestic animals. Up until now, the comparative
value of these lesions has been largely wasted, and it is now time to utilize some of
these animals in comparative cancer research.
The clinicopathologic features of canine OS have been described in considerable
detail in the veterinary literature [24-28]. I am reviewing the salient features ofcanine
OS to familiarize physicians with the remarkable similarity between OS in man and
dog.
INCIDENCE
OS appears to occur far more frequently in dogs than in man. Epidemiologic
studies of Alameda County in the San Francisco region indicate that the annual
incidence rate of bone tumors is 7.9/100,000 dogs, whereas the incidence of bone
tumors in man is only 1.1/ 100,000[18]. At the University ofPennsylvania Veterinary
Hospital (UPVH), OS accounted for 4.8 percent (123) of 2,550 histologically
diagnosed canine neoplasms from 1952-1963 inclusive [19]. Furthermore, the vast
majority of canine bone tumors are malignant, with OS being by far the most
common [27,28], whereas in man a large variety of benign bone neoplasms are also
observed [29]. In Alameda County when basal and squamous cell tumors were
excluded, the yearly cancer rates per 100,000 were 272.1 for humans compared to 360
for dogs [18].
Age
In one study of nearly 200 dogs, the median age was 7 years; average age 7.4 years;
mode 9 years and the range 1-15 years. Ten percent ofthe dogs were less than 2 years
of age and most of these were between 18 and 24 months[27]. Osteosarcoma in dogs
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less than one year of age is rare. The life expectancy of many breeds varies
considerably; in general, the giant breeds such as St. Bernards and Great Danes have
a lower life expectancy than the smaller breeds. The mean ages of the following
breeds with OS were St. Bernard-6.2 years; Great Dane-6.5 years; Boxer-7.3
years; and Irish setter-8 years [27].
The best comparison of canine and human ages was formulated by Lebeau [30]. A
12-year-old human equals a 1-year-old dog, and a 24-year-old human equals a 2-year-
old dog. From then on, each rise of four years in man is equivalent to an increase of
one year in the dog. Thus, a 56-year-old man would be equivalent to a 10-year-old
dog. Using this comparison, it is clear that canine OS occurs in a much older age
group (mean human equivalent age of 44 years) than does human OS. In most large
dogs, epiphyseal growth has ceased by 11 months, yet most OS occurs long after that
date. This later age of onset represents the major difference in the clinicopathologic
features of OS between the two species, as most human OS occurs during childhood,
adolescence, and early adulthood [29].
In almost all canine non-osseous malignancies (excluding lymphomas), there is an
increased risk with advancing age, but this is not so with OS where there is a sharp
rise in risk from 5-9 years with a sudden decrease from then on, suggesting that a
viral agent may be acting on dogs oflarge size and ofcertain genetic strains [19] (Fig.
1).
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Breed
Using artificial selection, man has created hundreds ofdifferent canine breed types,
all of which have different predilections for OS. That OS is a disease of large breeds
has long been recognized by practicing veterinarians. Indeed, the risk of OS in dogs
greater than 80 lb has been estimated to be 61-185 times the risk for dogs weighing
less than 20 lb [31]. In a review of 194 dogs with OS, only 4 percent weighed less than
25 lb [27]. Thus, OS is a size- rather than a breed-related disease. The major large
breeds affected are St. Bernard, Great Dane, Boxer, German Shepherd, and Irish
setter. The proportions of these breeds affected vary with the population characteris-
tics of dogs in the study area. The demonstration that OS was far more common in
large dogs was the basis of a study in children which indicated that children with
osseous malignancies were of larger skeletal size than those with non-osseous
neoplasms [32]. Achondroplastic dogs such as Dachshunds, and Bassett Hounds
have an exceedingly low incidence of OS [27]. The Beagle, an exceedingly common
breed for laboratory research in cancer, has an exceedingly low natural incidence of
OS [33]. Mixed breed dogs also have a much lower than expected incidence of OS,
probably because most of them tend to be small in size[27]. A study conducted at the
University of Pennsylvania Veterinary Hospital (UPVH) from 1952-1963 inclusive
indicated a breed-specific crude rate per thousand for OS of 2.1 for all breeds
compared to 6.9 for Boxers [19].
Genetic Factors
OS was found in six of 148 first-degree relatives of 21 index St. Bernard dogs with
histologically proved OS at the University of Pennsylvania Veterinary Hospital, but
was not found in any of the 110 first-degree relatives of 18 breed, age, and sex-
matched controls [34]. Analysis of a composite pedigree constructed from individual
four-generation pedigrees showed that all 21 index dogs were related. The average
coefficient of relationship for members of the OS-bearing group was significantly
higher than that for members of the control group. The average coefficient of
inbreeding of the OS-bearing group was lower than, but not significantly lower than,
that of the controls. This suggests that the presence of specific genes within certain
family lines, and not inbreeding per se, influences susceptibility to OS. The lack of
information on entire litters precluded the formal testing of specific genetic hy-
potheses, but examination of the pedigree excluded fully penetrant autosomal
dominant and X-linked recessive inheritance. Other monogenic models or more
complex modes, perhaps involving an interaction between genetic and environmental
factors, cannot be excluded, nor can vertical transmission of an infectious agent.
Based on the familial pattern of occurrence ofaffected dogs, developing a strain with
a high incidence of OS should be possible by selective breeding. A method for
identifying ancestors having a major contribution to the genome of the group of
index dogs was also described.
Sex
In 272 dogs with OS at the University of Pennsylvania Veterinary Hospital, 160
were males, and 112 were females, a M:F ratio of 1.5:1.0 [35]. In Alameda County,
California, canine bone tumors comprised 2.85 percent ofall cancers in males and 1.7
percent in females [17]. However, the sex ratios vary from breed to breed and these
differences are presently being evaluated.
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Site
In general, 77 percent of canine OS arises in the long bones, and 23 percent in the
flat bones. The four major weight-bearing bones (radius, humerus, tibia, and femur)
account for 70 percent of the OS [27]. Generally the forelimb to hind limb ratio is
nearly 2 to 1, but this ratio varies greatly from breed to breed, e.g., in 45 Boxers it was
1.2:1; whereas in 27 Great Danes it was 5.7:1. Furthermore, the long bone to flat
bone ratio varies widely from breed to breed, e.g., Boxer 2.1:1 and Great Dane 26: 1.
The five most common breeds appeared to fall into three major groupings relative to
site distribution: I. Irish Setters and German Shepherds; II. Boxers; III. Great Danes
and St. Bernards [27]. Metaphyseal origin is far more common than diaphyseal. The
major sites in the forelimbs are quite specific, proximal humerus and distal radius;
the elbow region is only infrequently affected. The predilection sites in the forelimb
appear to correlate with the approximate times of epiphyseal closure, e.g., the later
the time of closure, the greater the frequency of OS. The closure times of the
proximal and distal epiphyses of the humerus are 10-12 months and 8 months,
whereas those of the proximal and distal radial epiphyses are 9 months and 10-12
months, respectively. In the hind limb, OS is commonly found on both the proximal
and distal femur and tibia.
The major sites of axial skeleton OS are the skull (24 of 42 in one study) and the
ribs, particularly at the costochondral junction (8 of 42 cases). Other flat bones are
also involved but with far less frequency [27].
The tremendous variations in site frequencies is being studied further. Age, sex,
breed, and site information has been collected from 1,400 dogs with OS [35]. Analysis
of this data should give us a great deal of epidemiological information on the
interrelationships of these four parameters. The site predilections for naturally
occurring OS in man and dog differs from those observed with irradiation induction,
suggesting a cause other than bone-seeking radionuclides [36].
Clinical Findings
The two major findings are lameness and swelling. The median duration of
lameness is six weeks and 75 percent ofthe dogs have signs ranging from 1-9 weeks.
Clinical signs have been observed for six months, but this is rare. The lameness may
or may not precede the swelling. The affected area contains a hard fusiform and often
painless swelling. In severe cases lymphedema may be present distal to the tumor.
The growth of the mass is usually very rapid. Pathological fracture may be the
presenting sign in a few very lytic tumors, or it may occur later in the clinical course.
Clinical signs of pulmonary involvement are very uncommon initially, although
pulmonary signs are very common in the later stages [27]. Pulmonary metastases
commonly lead to the development of hypertrophic pulmonary osteoarthropathy
(Fig. 2), a syndrome that has already been studied in man and dogs [27,37]. New
concepts concerning its pathogenesis in man developed from studies of limb blood
flow initially performed in affected dogs [37].
Radiological Features
Canine OS shows all the features of a highly aggressive bone lesion with varying
admixtures of osteolytic and osteoblastic changes. Purely lytic tumors account for
approximately 5 percent of all OS [38]; pathological fractures are most common in
this group. Characteristic findings include sunbursting, Codman's triangle, irregular
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FIG. 2. Lateral radiograph of the forelegs of a dog.
The classical periosteal proliferative changes of hyper-
*,- *- _trophic osteoarthropathy are evident. Usually the pen-
osteal changes in the dog are more florid than in man.
Such limb lesions are usually secondary to metastatic or
_*-.~ primary lung neoplasms.
osteolysis, varying degrees of reactive periosteal new bone formation, and origin at a
metaphyseal site. All ofthesefindings are not always present in any given case[27,28]
(Figs. 3 and 4).
Pulmonary metastases (Fig. 5) are seen in less than 10 percent ofdogs at the time of
initial radiographic examination [25], but are extremely common at a median time of
18 weeks after limb amputation [39].
Histopathologic Features
Canine OS is identical to its human counterpart. The characteristic finding is the
direct formation of osteoid by the sarcoma cells (Fig. 6). Many canine OS also
produce varying amounts ofchondroid and collagen, so that a mixed type ofsarcoma
is present [27,28].
CONTRIBUTING FACTORS
Medullary Infarcts
These infarcts were first described in 1972 in four dogs, all of whom had
superimposed sarcomas [40]. Since then, six more cases have been detected by the
same authors. Nine of the 10 neoplasms were OS, and one was afibrosarcoma. Most
of the tumors arose in the tibia and femur. Most dogs were ofthe smaller breeds, and
4 of the 10 were Miniature Schnauzers, a breed rarely affected with OS. The cause of
the infarcts is not yet known, but intramedullary occlusive vascular disease appears
to play a role. Most dogs had multiple bony infarcts but only one site of sarcoma
formation. One dog presented with two primary OS. Similar cases have also been
reported in man [41]. We suspect that the stress of repair in the infarcted areas leads
to a greatly increased risk of OS.
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FIG. 3. Lateral radiograph ofthe foreleg of a Great
Dane with osteosarcoma of the distal third of the
radius-a classic site in this breed. The lesion is charac-
terized by extensive cortical lysis, sunbursting, Cod-
man's triangle, and a soft tissue mass.
FIG. 4. Dorsoventral radiograph of the foreleg of a
St. Bernard with an osteosarcoma of the distal radial
metaphysis. There is severe osteolysis extending proxi-
mally along the shaft of the radius as well as irregular
osteoblastic foci and a pathological fracture ofthe distal
ulna...-.X.
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FIG. 5. Lateral thoracic radiograph ofa
dog with metastases to the lungs and hilar
- area from a skeletal osteosarcoma.
Metallic Bone Implants
Since the first canine OS associated with metallic bone implants was observed in
1959 [24], an additional 11 case reports have been published [42-44]. Corrosion
products from these implants are suspected to have a carcinogenic potential. A
review of the case histories of the 12 reported canine cases revealed the following
significant features. The latency periods between the introduction of the metallic
implant and the development of the OS ranged from 1-11 years with a median time
of four years. Eight of the 12 tumors arose in the midshaft ofa long bone, most often
the femur (in OS unassociated with metallic implants, the metaphysis is a far more
common site than the diaphysis). The types ofimplants used were as follows: Jonas
splint-5; Jonas splint plus Steinman pin-1; bone plate-3; Steinman pin-2; and
Steinman pin plus cerclage wire-1. The Jonas splint, aself-retaining intramedullary
splint consists of three components. Metallurgical studies have indicated that each
component has a different composition and characteristics. These dissimilar metals in
contact with each other caused an electrolytic reaction that accelerated the corrosion
of the more ionic metals and increased the dispersion of metallic products into the
tissues. Chronic inflammation and drainage often developed afterthe insertion ofthis
device.
FIG. 6. Caine o sr o . o l.. ..
area of osteoid (arrows) is surrounded by
large pleomorphic neoplastic cells.
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In the past few years, six additional sarcomas (five osteosarcomas and one
fibrosarcoma) have been observed in association with metallic implants at the UPVH
[45]. Undoubtedly the number of implant-associated OS actually observed in dogs
greatly exceeds that which is recorded in the literature. The canine findings strongly
suggest that sarcomas in man are also associated with such devices far more often
than the three case reports in the present literature [46-48] would indicate.
Trauma
Four or five OS arising at the site of a pre-existing healed fracture have been
observed but such occurrences are exceedingly rare[26,35]. Immediate trauma seems
to have no relationship whatsoever to OS induction in dogs. Indeed, fractures are
exceedingly common in dogs, primarily because of automobile injuries, whereas OS
following such injuries (excluding metallic implant fixation) is very rare. While a
single traumatic incident plays no known role in the development ofcanine OS, small
oft-repeated traumas associated with weight bearing may be ofsome importance. The
large and particularly giant breed dogs bear more weight on their forelimbs than on
their hindlimbs, and correspondingly develop considerably more OS on their
forelimbs. Weight bearing and biomechanical balance are presently being studied by
the author in 1,400 dogs with OS.
THERAPY
Surgical Therapy
Surgical excision of OS in 65 dogs (limb amputation in 62 and rib removal in 3)
resulted in a median survival of 18 weeks. When this was combined with a
preoperative median duration ofclinical signs ofsix weeks, thetotal median duration
of disease was 24 weeks. The survival times ranged from three to greater than 578
weeks. Only 13.8 percent lived more than 9 months after surgery, and 11 percent
survived for one year. Two dogs were alive and free of disease more than two years
postoperatively, and four other dogs died of causes unrelated to osteosarcoma. No
correlation could be found between postsurgical survival time and the duration of
presurgical signs, the age, sex, or breed of the dog, the site of the tumor [39]; or the
radiographic features [38]. Histologic features of OS do not correlate with biological
behavior except in a few OS where the tumor is predominantly fibroblastic [49].
Recently a few dogs have beentreated by segmental resection ofan affected ulna or
fibula followed by chemotherapy [50].
Because many dogs with OS are euthanatized rather than dying a natural death,
there is some variability in the survival results obtained, e.g., some owners may have
their pets destroyed as soon as radiographic evidence oflung metastasis is detected,
whereas others may wait until terminal signs of disease become evident. For this
reason, the first detection of metastatic disease radiographically is a more objective
and sensitive indicator of treatment failures. The median interval between amputa-
tion and the onset of radiographically visible metastatic lung disease was 73 days
(range, 50-160 days) in nine dogs treated by amputation and doxorubicin [51].
Immunological Monitoring
Cell-mediated reactivity (CMR) and serum blocking activity (SBA) were assessed
sequentially in 11 dogs treated surgically for OS. Six dogs received postoperative
BCG and five served as controls. SBA decreased significantly soon after surgery in
both groups. No consistent relationship between CMR and SBA and clinical
355metastasis was detected in the postsurgical period in either group [52,53]. Presently
our sequential immunologic monitoring studies include lymphocyte transformation
with various mitogens, leukocyte migration inhibition, and determinations ofeffector
T lymphocytes by the rosette technique both preoperatively and during adjuvant
therapy. Immunological studies of canine OS are still in their infancy.
Immunotherapy
Very little work has been done in dogs with OS. Six dogs given freeze-dried BCG
(Glaxo strain, 50-250 x 106 viable organisms) intravenously 1, 2, 4, and 8 weeks after
amputation had a median survival of 52 weeks (range 16-65 weeks) as compared to a
mean survival of 11 weeks (range 6-17 weeks) for five control dogs [54].
Another group of six dogs was treated postsurgically with intradermal BCG
(Trudeau strain, 1.5 x 107 viable organisms) at two-week intervals for one year. Their
median survival was 40 weeks as contrasted to five controls having a median survival
of 13 weeks [53]. However, when the results of the two studies were combined, there
was a statistically significant difference in survival times (p<0.01) even though the
strain of BCG and route of administration were different. More recently I.V.
administration of Glaxo BCG given to 20 dogs following amputation for OS was
associated with a mean survival time of 25 weeks. Seven of these dogs were alive one
year later [55]. Although these early results appeared encouraging, a recent con-
trolled study ofdogs with OS indicated that survival times in 11 amputated dogs were
similar to that of 12 dogs that were amputated and given postoperative BCG and
autologous tumor homogenate [56].
Chemotherapy
The small numbers of dogs treated by chemotherapy that have been reported and
the variation in treatment plans makes detailed assessment of the results rather
difficult at present. In 1964, 17 dogs with malignancies of bone, most of which were
OS, were treated with triethylene glycol diglycidyl ether. The drug was given intra-
arterially to five dogs, by regional perfusion to five dogs, and using a technique to
occlude the aorta and limit the drug to the cranial half of the body, it was
administered to three others. Regression of the neoplasms occurred in 12 dogs but
was maintained for two months or more in only five of these. The longest period of
regression was five months. Following perfusion there was local relief of pain, but
edema often developed and in four dogs gangrene was observed [57].
In 1978, 14 dogs treated by amputation and doxorubicin (30 mg/iM2 of body
surface area) were reported. Doxorubicin therapy was initiated three weeks after
surgery, and was given intravenously every three weeks for 24 weeks. Drug therapy
was discontinued if pulmonary metastases were detected radiographically. The
median survival was 15 weeks (range 52-368 days) and 14 percent survived more than
one year [51]. These findings were almost identical to that following amputation
alone in 65 dogs [39].
At present, several chemotherapy or chemotherapy-immunotherapy protocols are
being evaluated, but the studies have yet to be completed.
A major problem in canine therapy trials involves the cost to the owner. Hopefully,
a greater appreciation of the value of these naturally occurring animal models will
make money available to help owners defray some of the costs for multimodality
therapy.
356 ROBERT S. BRODEYCANINE OSTEOSARCOMA: A MODEL FOR HUMAN OSTEOSARCOMA
Radiation Therapy
Prophylactic lung irradiation using 600 R on two occasions at a one-week interval
was found to be of no value in dogs with OS [58]. Seventeen dogs had their affected
limbs treated with fractionated doses of 4,000-4,500 R of X-irradiation from a
15 MeV linear accelerator giving 120-130 rads/minute with 100 percent penetration at
3 cm in tissue. Doses of 1,000 R were given at weekly intervals. Reduction in pain was
remarkable but mean pain-free survival was only four months with a range of 1-12
months [59].
Combined Modality Approach
Many exciting possibilities exist for future studies. If it can be shown that micro-
and macrometastatic disease can be successfully treated medically, then trials
concentrating on limb-saving technics can begin. Combinations of irradiation with
hyperthermia and radiation sensitizers may be of considerable value in treating the
primary tumor with orwithout segmental resections. Carefully designed multimodal-
ity clinical trials in dogs with OS should generate valuable biological data in a much
shorter time than is possible in man.
PROGNOSTIC VARIABLES
A recent necropsy study of 144 untreated dogs with OS indicated that 49 had
metastases, 44 of which involved the lungs [60]. Histologic subtype (excluding the
fibrosarcomatous type) and grade, mitotic index, amount of intercellular substance,
numbers of peritumorous lymphoid and plasma cells, duration of clinical signs.,
breed, sex, and age ofthe dogs were not ofprognostic significance. The occurrence of
pulmonary metastases was closely correlated with tumor diameter and volume as well
as with extension of the OS into adjacent soft tissues and the origin of the OS in
bones of the hindlimbs. Future design of prospective randomized clinical trials in
dogs should take these prognostic variables into account so that patient groups are
biologically balanced to ensure more accurate evaluation of the results.
ADVANTAGES OF STUDYING NATURALLY OCCURRING CANINE OS
1. OS is much more common in dogs than in man. It is a strikingdisease clinically
and usually is easily recognized in the field. Centers carrying out therapeutic trials or
other studies have not had difficulty attracting cases from local veterinarians. At the
UPVH we have seen approximately 50 dogs with OS duringthe past year alone. This
great increase in case load has primarily been due to the combined surgical, chemo-
and immunotherapy trial now under way.
2. There is a tremendous similarity in the clinical, radiological, and histological
features of OS in dogs and man (Table 1), making an affected dog of tremendous
value for a variety ofetiological, epidemiological, immunobiological, and therapeutic
studies.
3. As both dog and man often share a common environment, similar causative
factors may be operative in both species. Dogs with OS and other neoplasms may be
important environmental monitors for such diseases in man. Future epidemiological
research should correlate human OS incidence data with that in other species in given
geographic areas.
4. The large size of the canine patients makes them ideal for obtaining adequate
samples of blood, tumor tissue, etc.-a problem that is often of major importance in
laboratory rodents.
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TABLE I
Comparative Features of Canine and Human Osteosarcoma
Features Dog Man
Skeletal size
Age
Genetic implications
Conditions known to
predispose
Incidence (Alameda Co.,
California
Male to female ratio
Major sites of
predilection
Radiographic appearance
Clinical course
Median time to appearance
of lung metastases
after amputation
Major cause of
treatment failure
Hypertrophic pulmonary
osteoarthropathy
Large breeds (> 80 lb) 60-180
times more susceptible than dogs
< 20 lb [31].
Major peak 6-9 yr (40-52 yr
in human equivalent) with a minor
peak 1-2 yr ( 12-24 yr human
equivalent) [27,30].
Familial tendency recently
observed in St. Bernards, Specific
genes may be involved [34].
Medullary infarction of bone [39],
metallic implants in bone [24,41-44].
No known counterpart to Paget's
disease.
7.9/100,000 [17,18]
1.6:1.0 [35]
Major weight-bearing bones
(radius, humerus, tibia, and
femur)-metaphyseal origin [35].
Aggressive, osteolytic, and
osteoblastic. Codman's triangle,
sunbursting, etc. [35].
Rapidly progressive, early
lung metastasis [35].
10 weeks [51].
Metastases to lungs [39].
As many as 25% with lung
metastases [27].
Children of larger bony
stature at greater risk [32].
Bimodal age peaks-major
peak 10-25 yr, minor peak
50-60 yr (superimposed on
Paget's disease) [29].
Occasional familial tendencies [68].
Medullary infarction of
bone [41], metallic implants
in bone [46-48]. Paget's
disease [29].
1.1/100,000 [18]
1.6:1.0 [29]
Major weight-bearing bones
(distal femur, proximal tibia)
-metaphyseal origin [29].
Aggressive, osteolytic, and
osteoblastic. CGdman's triangle,
sunbursting, etc. [29].
Rapidly progressive, early
lung metastasis [29].
10 months [67].
Metastases to lungs [67].
Not recorded with lung
metastases [29].
5. Veterinary oncology expertise has risen sharply in the last decade. An increasing
number ofveterinary schools and otherinstitutions have oncology sections and many
of these are carrying out various therapy protocols. Since most ofthese protocols are
on an outpatient basis, the research costs are greatly reduced.
6. Recent pedigree studies indicate we now have the necessary genetic knowledge
to develop strains ofdogs with heightened susceptibility toOS. Such strains would be
invaluable, particularly in studying etiological factors and host-tumor interactions in
the early stages of the disease.
7. Many owners of dogs with OS would be very grateful to know that treatment or
other related investigations in their pets might also help humans with OS. Because
cancer will afflict one ofeveryfour persons in the U.S., it is reassuring to such owners
to know that therapeutic research in their pet may someday help them or their
families.
8. Rat and mouse bone is non-osteonal, i.e. lacks Haversian canals, unlike bone in
rabbits, all domestic mammals, and man[61]. Thus the development ofOS in species
having osteonal bone most closely approximates OS in man.
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DISADVANTAGES
1. The large size of affected dogs (95 percent weigh more than 30 lb) means that
housing them will often demand larger kennel areas and increased feeding costs.
Similarly, drug costs will be greater because of the large size of many of the patients
when compared to laboratory rodents. However, most of these objections can be
circumvented by relying primarily on outpatient studies.
2. Beautifully controlled studies such as those in experimental murine hosts are
not as likely in canine OS because ofthe variability ofowner responses to the stress of
treatment. Similar problems are encountered with human patients and theirfamilies.
OTHER NATURALLY OCCURRING OS
Dogs and humans are the two mammalian species most commonly affected.
Domestic cats are the third most common species to develop OS. The most common
sites in cats appear to be the humerus, femur, tibia, and skull [62]. Flat bones are
involved as commonly as long bones, and the hindlimbs are involved more often than
the forelimbs [35]. It has been suggested that feline OS has a lower metastatic
potential than in man or dog [51], but more cases must be studied before this can be
documented. Many of the clinical, radiological, and pathological features of feline
OS closely approximate those ofOS in man and dog. The major difference is that OS
in cats occurs primarily in older animals [62]. Almost no information relevant to
therapy has been published. Three cats with limb OS were treated by amputation and
postoperative doxorubicin. One was euthanatized 180 days after surgery because of
unrelated disease, another at 143 days because of lung metastases. A third cat was
alive 436 days postoperatively despite the presence of lung metastasis [51].
Osteosarcoma developed in the thoracic vertebrae of three piglets and in the
lumbar vertebrae of another piglet in England. Ages of affected animals were 4, 5, 9,
and 11 weeks. Two of the piglets originated from the same farm. In India OS of the
ribs was diagnosed in two pigs that were nine months old [63]. More careful studies
of young pigs may reveal that OS is more common than is presently realized.
Interestingly the age incidence of pigs with OS closely approximates that of humans
with OS.
In sheep OS is rare, although chondrosarcoma arising from the rib cage has been
reported in a number ofinstances[64]. The ultrastructure of an OS obtained from the
pelvic region ofan adult ewe was studied. The pattern ofdistribution ofthe organized
interchromatin-like granules in almost every tumor cell nucleus was similar to that
observed in human rhabdomyosarcoma where a viral origin is suspected [65].
In all other domestic mammals OS is exceedingly rare; however, OS has been
reported in a few other subhuman primates, e.g., an adult male squirrel monkey had
an OS of the proximal humerus. It was reported to be clinically well 20 months after
amputation. A 10-month-old lemur developed an OS in the carpal region. No
metastases were detected at post mortem [66].
CONCLUSION
This review ofnaturally occurring canine OS (it also occurs in cats, swine, etc.) and
artificially induced OS in rabbits, rodents, swine, and dogs indicates that awealth of
biological data already exists onthis deadly disease. It is the responsibility ofall ofus
interested in the biology and treatment of cancer to glean as much knowledge as
possible from these mammalian systems, each of which offers many clues. Such a
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broad-based knowledge will undoubtedly influence our conceptual approach to
research, and clinical options. To concentrate solely on OS in humans and rodents
greatly limits these options, for as Robert Burns so clearly stated, "the best laid
schemes of mice and men gang aft a-gley."
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